-
-
Overview
-
Please contact us at for specific academic pricing.
Background
MK-8033 is a c-MET inhibitor in clinical trials. MK8033 is a selective small-molecule inhibitor, ATP competitive. Phase I investigation of the cMet inhibitor MK-8033 is ongoing. Plans include a trial of this agent in refractory colorectal cancer, with pre- and post-treatment biopsies to evaluate for relevant molecular signatures.
-
- Properties
-
Overview